Spire Healthcare Group plc (LON:SPI - Get Free Report)'s stock price rose 14.1% during trading on Saturday . The stock traded as high as GBX 256.50 ($3.47) and last traded at GBX 247 ($3.34). Approximately 9,747,062 shares traded hands during trading, an increase of 563% from the average daily volume of 1,469,073 shares. The stock had previously closed at GBX 216.50 ($2.93).
Analyst Ratings Changes
Several equities analysts recently weighed in on SPI shares. Berenberg Bank reaffirmed a "buy" rating and issued a GBX 280 price objective on shares of Spire Healthcare Group in a research note on Thursday, July 31st. JPMorgan Chase & Co. lowered their target price on Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of GBX 294.33.
Read Our Latest Report on SPI
Spire Healthcare Group Price Performance
The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74. The firm has a market capitalization of £947.58 million, a PE ratio of 5,119.57, a P/E/G ratio of 1.06 and a beta of 0.96. The company has a 50-day moving average price of GBX 218.99 and a 200-day moving average price of GBX 203.96.
Spire Healthcare Group (LON:SPI - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported GBX 4.10 earnings per share for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. Sell-side analysts forecast that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.
About Spire Healthcare Group
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Read More
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.